![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 27, 2015 9:59:04 AM
BEVERLY, MA--(Marketwired - Jan 27, 2015) Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to learn this morning that President Barack Obama will call upon Congress to double funding dedicated to fighting drug-resistant bacteria to $1.2 billion in his annual budget request scheduled to be released on Monday.
As part of the new budget plan, the President wants to see a sharp increase in funding for the National Institutes of Health and Biomedical Advanced Research and Development Authority (BARDA) for antibacterial research and diagnostics, as well as additional funds for the U.S. Food and Drug Administration for evaluation of new antibiotic drugs. Experts have been warning of the great need for new drugs to combat “superbugs,” deadly bacteria that do not respond to most of today’s approved drugs, with the Obama administration calling antibiotic resistance a serious threat to public health and the economy in an Executive Order last September.
The Centers for Disease Control and Prevention estimates that antibiotic resistance causes about two million illnesses each year and is responsible for 23,000 deaths in the United States. Perhaps nothing exemplifies how deadly superbugs can be quite like the outbreak of Carbapenem Resistant Enterobacteriaceae (CRE) Klebsiella pneumoniae at the National Institute of Health’s Clinical Center in 2012 that killed 11 people. Last month, Forbes published an article discussing the potential danger of athletes and visitors contracting and spreading drug-resistant infections at the upcoming 2016 Olympics in Rio De Janeiro following the Brazil Health ministry determining water in Guanabara Bay contained multi-drug resistant organisms carrying carbapenem-resistant Klebsiella pneumoniae enzymes.
Cellceutix’s research partners have been awarded $2 million in grants from the National Institute of Health, including a recent grant of $500,000 for research on drug-resistant Gram-negative infections.
Cellceutix believes that with its defensin-mimetic portfolio it has the most advanced class of antibiotics to attack and destroy this and possibly other superbugs. The killing ability of the compound against carbapenem-resistant Klebsiella pneumoniae is astounding. Cellceutix is presently conducting safety testing and subsequently will determine if the drug is to be advanced to clinical trials. The Company continues to work with its collaborators at Fox Chase to develop a novel drug candidate as quickly as possible to be ready for the Rio 2016 Olympics where this may become a serious threat.
“The recent Ebola outbreak overseas and constant warnings about the seriousness of drug-resistant superbugs should tell people that we’re playing a serious game of Russian roulette with bacterium that defy today’s drugs,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “This news of a proposed budget increased focusing on developing new antibiotics fits perfectly with our business model and we hope it will lead to not only additional grants for our novel drugs, but also even more opportunities to expedite development of our drugs to combat these deadly pathogens.”
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM